- Home
- IVDA vs RNAZ Comparison
IVDA vs RNAZ Comparison
Compare IVDA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVDA | RNAZ |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.6M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IVDA | RNAZ |
|---|---|---|
| Price | $0.42 | $3.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.4M | 13.3K |
| Earning Date | 05-12-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,468,279.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.98 | N/A |
| 52 Week Low | $0.21 | $3.30 |
| 52 Week High | $2.24 | $20.99 |
Technical Indicators
Market Signals| Indicator | IVDA | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 61.93 | 29.42 |
| Support Level | $0.24 | N/A |
| Resistance Level | $0.42 | $6.15 |
| Average True Range (ATR) | 0.05 | 0.50 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 52.18 | 3.58 |
Price Performance
Historical ComparisonAbout IVDA Iveda Solutions Inc.
Iveda Solutions Inc offers smart city technologies globally, offering AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products). Geographically, the company operates in USA and Taiwan, majority of its revenue is generated from Taiwan.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.